Effect of anisodamine on regional cerebral blood flow in patients with dizziness: A randomized single-blind controlled trial

Abstract

This study aimed to evaluate the effect of anisodamine on regional cerebral blood flow (rCBF) and associated dizziness. 150 patients with dizziness induced by low rCBF were divided randomly into groups A (n = 60; anisodamine), P (n = 60; alprostadil), and C (n = 30; normal saline). rCBF and dizziness severity were evaluated. After treatment, rCBF values increased both in groups A and P. The subjective symptom of dizziness improved in 55 (91.7%) patients with the DHI score decreasing from 65.9 ± 5.4 to 23.1 ± 7.4 in group A, and the symptom improved in 37 (61.7%) patients with the DHI score decreasing from 66.8 ± 6.2 to 43.8 ± 8.6 in group P. The difference in DHI score and rCBF values in group A was more significant than that in group P. Anisodamine could increase rCBF and alleviate symptoms of dizziness more effectively than alprostadil.